ZTS Dividends
Zoetis Inc. (ZTS) pays $2.06 in dividends per share, with a current dividend yield of 2.53%. The company has dividend history for 12 consecutive years.
ZTS Dividend Summary
2.53%
$2.06
34.16%
42.77%
Consecutive Years
12
Next Ex-Dividend Date
Jul 20, 2026
Next Payment Date
Sep 1, 2026
ZTS Dividends per Share (Nominal History)
View full nominal table listThis step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency.
ZTS Dividends CAGR Chart
Zoetis Inc. (ZTS)
Annual Dividend History
| Year | Dividend/Share | YoY Growth |
|---|---|---|
| 2026(YTD) | $1.59 | — |
| 2025 | $2.00 | +15.74% |
| 2024 | $1.73 | +15.20% |
| 2023 | $1.50 | +15.38% |
| 2022 | $1.30 | +30.00% |
| 2021 | $1.00 | +25.00% |
| 2020 | $0.80 | +21.95% |
| 2019 | $0.66 | +30.16% |
| 2018 | $0.50 | +20.00% |
| 2017 | $0.42 | +10.53% |
| 2016 | $0.38 | +14.46% |
| 2015 | $0.33 | +15.28% |
| 2014 | $0.29 | N/A |
| 2013 | $0.20 | N/A |
Quarterly Dividend History
| Quarter | Dividend/Share | YoY Growth |
|---|---|---|
| Q3 2026 | $0.53 | +6.00% |
| Q2 2026 | $0.53 | +6.00% |
| Q1 2026 | $0.53 | +6.00% |
| Q4 2025 | $0.50 | +15.74% |
| Q3 2025 | $0.50 | +15.74% |
| Q2 2025 | $0.50 | +15.74% |
| Q1 2025 | $0.50 | +15.74% |
| Q4 2024 | $0.43 | +15.20% |
| Q3 2024 | $0.43 | +15.20% |
| Q2 2024 | $0.43 | +15.20% |
| Q1 2024 | $0.43 | +15.20% |
| Q4 2023 | $0.38 | +15.38% |
| Q3 2023 | $0.38 | +15.38% |
| Q2 2023 | $0.38 | +15.38% |
| Q1 2023 | $0.38 | +15.38% |
| Q4 2022 | $0.33 | +30.00% |
| Q3 2022 | $0.33 | +30.00% |
| Q2 2022 | $0.33 | +30.00% |
| Q1 2022 | $0.33 | +30.00% |
| Q4 2021 | $0.25 | +25.00% |
| Q3 2021 | $0.25 | +25.00% |
| Q2 2021 | $0.25 | +25.00% |
| Q1 2021 | $0.25 | +25.00% |
| Q4 2020 | $0.20 | +21.95% |
Dividend Yield Metrics
- Current Yield
- 2.53%
- Average Yield (TTM)
- 2.53%
- Average Yield (3Y)
- 2.14%
- Forward Yield on Cost (3Y)
- 5.05%
- Forward Yield on Cost (5Y)
- 8.02%
- Forward Yield on Cost (10Y)
- 25.46%
Payout Ratio Analysis
- Payout Ratio (Current)
- 34.16%
- FCF Payout Ratio
- 42.77%
- Payout Ratio (3Y Avg)
- 31.43%
- Payout Ratio (5Y Avg)
- 29.28%
- FCF Payout (3Y Avg)
- 38.56%
- FCF Payout (5Y Avg)
- 37.79%
Dividend Coverage
About Zoetis Inc.
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck